Member Info for Bmhltd

Another nice find, thanks Vares…

I can assure you I’m not paid to promote anything, and find that laughable but there you are.

Wrt offers on the table Juho mentioned at CMD day 2024 that offers were on the table and had been discussed that they would be double treble the magnitude of what they were then post P2 data readout which has now been, passed and delivered a great result.

The CAR-T thing was talked about by Juho in the recent podcast which I posted to this board.

Does that answer your questions?

Happy to answer any. The reason I invested is because I saw this ticks many of the boxes big pharma look for in an acquisition scenario having researched a lot of biotechs and remain invested in several.

This is my favourite, has all the regulatory tail winds and is at the point Pharma like to strike amidst the LoE backdrop I discussed in my earlier post today.

Leaving it any later ensures a bidding war.

Juho has talked about getting the balance right at the H1 earnings call of not giving away too much and maximising shareholder value. The board and others are very aligned with PI’s like you and I.

Hope this is helpful.

All the information is there in the public domain if you just look and listen.

Which doesn’t guarantee anything but helps to inform my investment decisions.

We also have to consider that none of the market size factor in any expansion into other indications such as those in the pipeline, see the most recent deck, ie AML, breast, STS, sarcoma, lung cancer etc and recently Juho mentioned CAR-t which could be one most haven’t even thought about and could be used to reduce t-cell dosing, minimise Tox such as CRS, and overcome treatment resistance / increase efficacy.

Lots going on in the background, just need some clarity and cash to get us to the big league, of which there is plenty out there and a vast loss of exclusivity cliff edge approaching which mean big pharma need to spend big to overcome and keep their pipelines in a strong position.

Thanks for the mention Howard.

Not sure what you are insinuating but I have suggested there is always risk and have laid them out in prior posts.

However I believe, and have laid out that there could be a raise at or around this level, I believe €2 was what I suggested, if needed, which would be a value accretive raise given what it is for, ie, commencing the registrational trial. I do believe offers will already be on the table and trust the board will make the right decision on how to proceed if the deals on the table aren’t worth giving away as much as is demanded at this stage.

It could be that a prelude to a deal is a raise as it becomes clear we can go it alone but I suspect any potential suitors partners would want to control the pivotal trial thus expect a deal prior to starting would be my base case.

The main risk would be market volatility due to liquidity issues perhaps as the result of a serious slow down / debt crisis in major developed markets, however these things don’t tend to last unless a major crisis was to ensue.

However at this stage, and the current market cap, believing in the data, such as doubling the CR rate, and it continuing to play out as such and the market size is 12bn usd, the furthest we will likely take it is to the randomised data readout of 120 patients 40 / 40 /40 on 1mg / 3 mg / placebo.

At which point I would be very surprised to not see is taken out in the multi-billions. A decent risk reward for a one to two year timeframe.

Nobody can predict the share price moves on a day to day basis, and I don’t claim to be able to, but I believe we have the team, drug and options to get us to a far better place in a reasonable time frame.

I still believe as my base case a deal will be done for the reasons I have laid out prior to a significant raise, a small one is possible to augment the cash balance in the interim but then we also have options with the CLN.

Rate certainty looks to be coming more clear at today’s Fed meeting and the end of the year could be the most likely for a deal…

Biotech is volatile and not for the faint hearted.

Hope that helps…

Faron just laid out a $12 billion USD market in the US and EU5 in HR MDS, alone, for Bex!

Tapping just 25% of that puts us at $3Bn USD per annum.

On a price / sales multiple of 3-5x, you do the math….!

Probably nothing to get excited about…!

Great new deck 👍🏻

Great new deck 👍🏻

Yes watched it not long after posted, very enjoyable and great presenter who dug into the weeds and opened up the salient points rather well.

Yep, I trust there will be plenty of interest in the recently started IB bank led deal making process, hoping Juho & the IB bank are busy building that competitive tension that will hopefully net us a great deal.

Here’s hoping.

Not had chance to watch yet but looks like it could be a good one…

https://youtu.be/VtijaB1Wamk?si=ARf5xiZ7gLv1TbUZ

Https://www.ainvest.com/news/faron-pharmaceuticals-q1-2025-performance-strategic-buying-opportunity-market-correction-2509/

Https://www.tipranks.com/news/ratings/faron-pharmaceuticals-oys-bexmarilimab-shows-promise-in-hr-mds-trials-with-fda-support-reinforcing-buy-rating-ratings

Analyst of H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy, retaining the price target of £10.00.

And maybe read this one last.

https://chatgpt.com/s/t_68c3c28bf8bc81919873d4e1094e994e

Confident we can do a very good deal at this stage, that makes the current Mcap look the gift that I feel it is.

Perhaps a small raise in the interim if negotiations become protracted but would expect the further $10m CLN to be enough to get us over the line, if absolutely necessary.

GLA

Perhaps read this one first if interested…

https://chatgpt.com/s/t_68c3c02c361c8191a771e9d140b2bd92

A couple of questions mulled over by ChatGPT on Farons options for deals, hopefully pick up investor spirits, as the grind down weighs on optimism.

https://chatgpt.com/s/t_68c3bf5b0bb08191862c532ed38cfe3b

https://chatgpt.com/s/t_68c3bf3496b88191956bc0c621ef7075

Https://fican.fi/tapahtumat/fican-science-webinaari-shaping-the-future-of-high-risk-mds-with-bexmarilimab/

Or hopefully forced to go long by news flow that brings us out from the shadows and refutes any semblance of this price being logical given precedent transactions..

Likely some accumulation going down by some bigger fish, imo.

They will at some point meet their quota and have a strong interest in a higher stock price and bid up the price rather than squeezing it down with layering, spoofing, shorting like they are probably doing now.

Wouldn’t want to be out when they finish and go long.

AIMO!

Zzzzz

Haha

Zzzzzzzzzzz

Https://chatgpt.com/s/t_68ba83e7ff648191b05d843d1bfc55de